A US FDA advisory committee backed the approval of Janssen R&D LLC’s depression drug esketamine but said the parameters of a proposed Risk Evaluation and Mitigation Strategy (REMS) need to be better defined, particularly as to the types of facilities where the drug will be administered.
The Psychopharmacologic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee on Feb. 12 strongly endorsed the efficacy,...





